Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Costas Andreas Lyssiotis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9309-6141; OpenAlex author ID A5085494535; NIH RePORTER profile ID 8623036. Sources: OpenAlex.

Their work

Papers
47 (first author 4, last author 14)
Trials
0
Grants
5
Labs led
1
Collaborators
219
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 5 papers · 2019: 3 papers · 2020: 4 papers · 2021: 8 papers · 2022: 4 papers · 2023: 6 papers · 2024: 2 grants · 2025: 5 papers · 2026: 5 papers, 3 grants

Papers 47

  1. Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/s41586-026-10488-6↗
  2. Lysosomal metabolism in pancreatic cancer and its crosstalk with host physiology. Last author DOI 10.1101/gad.353702.126↗
  3. Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0823↗
  4. Asynchronous Evolution of Epithelium and Stroma Differentiates Precursor Lesions from Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-25-2001↗
  5. Targeting CCR1 Remodels the Tumor Microenvironment and Relieves Immunosuppression in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-25-1300↗
  6. Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1038/s41419-025-08082-1↗
  7. Targeting PIKfyve-driven lipid metabolism in pancreatic cancer. Co-author DOI 10.1038/s41586-025-08917-z↗
  8. DUSP6 is upregulated in metastasis and influences migration and metabolism in pancreatic cancer cells. Co-author DOI 10.1038/s41598-025-12967-8↗
  9. Multidimensional analyses identify genes of high priority for pancreatic cancer research. Last author DOI 10.1172/jci.insight.174264↗
  10. Aspartate Transaminases Are Dispensable for Pancreatic Development and Pancreatic Cancer Progression Last author DOI 10.64898/2025.12.17.694916↗
  11. Pancreatic cancer: Advances and challenges. First author DOI 10.1016/j.cell.2023.02.014↗
  12. An unexpected pathway to polyamines in pancreatic cancer. First author DOI 10.1016/j.molcel.2023.05.014↗
  13. Increased glucose availability sensitizes pancreatic cancer to chemotherapy. Co-author DOI 10.1038/s41467-023-38921-8↗
  14. Uridine-derived ribose fuels glucose-restricted pancreatic cancer. Last author DOI 10.1038/s41586-023-06073-w↗
  15. Ras-dependent activation of BMAL2 regulates hypoxic metabolism in pancreatic cancer Co-author DOI 10.1101/2023.03.19.533333↗
  16. Arginase 1 is a key driver of immune suppression in pancreatic cancer. Co-author DOI 10.7554/elife.80721↗
  17. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells. Last author DOI 10.1038/s43018-022-00463-1↗
  18. NetrinG1+ cancer-associated fibroblasts generate unique extracellular vesicles that support the survival of pancreatic cancer cells under nutritional stress. Co-author DOI 10.1158/2767-9764.crc-21-0147↗
  19. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Last author DOI 10.7554/elife.73245↗
  20. Multiomic characterization of pancreatic cancer-associated macrophage polarization reveals deregulated metabolic programs driven by the GM-CSF-PI3K pathway. Last author DOI 10.7554/elife.73796↗
  21. GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. Last author DOI 10.1038/s41467-021-24859-2↗
  22. Nutrient profiling reveals extracellular uridine as a fuel for pancreatic cancer through uridine phosphorylase 1 Last author DOI 10.1101/2021.06.07.447448↗
  23. ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer. Co-author DOI 10.1101/gad.344184.120↗
  24. The biological underpinnings of therapeutic resistance in pancreatic cancer. Co-author DOI 10.1101/gad.348523.121↗
  25. Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-κB-Mediated Production of CXCL1. Co-author DOI 10.1158/0008-5472.can-20-3929↗
  26. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3715↗
  27. Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages. Co-author DOI 10.26508/lsa.202000935↗
  28. Hyaluronic acid fuels pancreatic cancer cell growth. Last author DOI 10.7554/elife.62645↗
  29. A covalent small molecule inhibitor of glutamate-oxaloacetate transaminase 1 impairs pancreatic cancer growth. Last author DOI 10.1016/j.bbrc.2019.11.130↗
  30. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-020-0947-8↗
  31. Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer. Co-author DOI 10.1038/s43018-020-00121-4↗
  32. Clonal Heterogeneity Supports Mitochondrial Metabolism in Pancreatic Cancer Last author DOI 10.1101/2020.05.15.098368↗
  33. Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Last author DOI 10.1016/j.cmet.2019.02.001↗
  34. Metabolism and epigenetics of pancreatic cancer stem cells. Co-author DOI 10.1016/j.semcancer.2018.09.008↗
  35. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-019-0368-8↗
  36. Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bmcl.2018.04.061↗
  37. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Co-author DOI 10.1038/s41467-018-07472-8↗
  38. The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and D… Co-author DOI 10.1097/mpa.0000000000001037↗
  39. Tumor cross-talk networks promote growth and support immune evasion in pancreatic cancer. Last author DOI 10.1152/ajpgi.00416.2017↗
  40. Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.97422↗
  41. Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer. First author DOI 10.1016/j.ccell.2016.12.006↗
  42. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.06.004↗
  43. Adipocytes promote pancreatic cancer cell proliferation via glutamine transfer. Co-author DOI 10.1016/j.bbrep.2016.06.004↗
  44. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone. Co-author DOI 10.1186/s40170-015-0137-1↗
  45. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/nature13611↗
  46. Targeting metabolic scavenging in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-13-2570↗
  47. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. First author DOI 10.1038/nature12040↗

Grants 5

  1. Targeting Uridine Metabolism in Pancreatic Cancer R01CA313980↗
  2. Intratumoral Metabolic Crosstalk Promotes Therapeutic Resistance in Pancreatic Cancer R37CA237421↗
  3. Fibroblast orchestration of the immune response in pancreatic cancer U01CA274154↗
  4. Targeting metabolic stress to induce pancreatic tumor cell death R01CA244931↗
  5. Stromal metabolism promotes therapeutic resistance in pancreatic cancer R01CA248160↗

Closest collaborators

The 25 strongest of 219 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marina Pasca di Magliano · 24 shared papers, 1 shared grant, 2018–2026 · strength 4.15
  2. Timothy L. Frankel · 10 shared papers, 1 shared grant, 2016–2026 · strength 2.15
  3. Christopher J. Halbrook · 16 shared papers, 2017–2023 · strength 1.87
  4. Howard C. Crawford · 10 shared papers, 1 shared grant, 2019–2026 · strength 1.82
  5. Filip Bednar · 10 shared papers, 2019–2026 · strength 1.54
  6. Eileen S. Carpenter · 11 shared papers, 2020–2026 · strength 1.43
  7. Zeribe C. Nwosu · 10 shared papers, 2021–2026 · strength 1.25
  8. Li Zhang · 9 shared papers, 2019–2025 · strength 1.03
  9. Dominik Awad · 4 shared papers, 2023–2026 · strength 0.94
  10. Nina G. Steele · 8 shared papers, 2020–2025 · strength 0.90
  11. Rosa Elena Menjivar · 6 shared papers, 2021–2026 · strength 0.88
  12. Jiaqi Shi · 5 shared papers, 2019–2026 · strength 0.84
  13. Padma Kadiyala · 4 shared papers, 2023–2026 · strength 0.75
  14. Yaqing Zhang · 7 shared papers, 2019–2023 · strength 0.73
  15. Samantha B. Kemp · 7 shared papers, 2019–2025 · strength 0.73
  16. Haoqiang Ying · 8 shared papers, 2013–2026 · strength 0.68
  17. Lewis C. Cantley · 8 shared papers, 2013–2026 · strength 0.63
  18. Ahmed M. Elhossiny · 3 shared papers, 2026 · strength 0.61
  19. Katelyn L. Donahue · 5 shared papers, 2020–2026 · strength 0.61
  20. Alec C. Kimmelman · 8 shared papers, 2013–2026 · strength 0.60
  21. Arul M. Chinnaiyan · 2 shared papers, 2025–2026 · strength 0.60
  22. Caleb Cheng · 2 shared papers, 2025–2026 · strength 0.60
  23. Samuel Andrew Kerk · 5 shared papers, 2021–2025 · strength 0.59
  24. Vaibhav Sahai · 4 shared papers, 2020–2026 · strength 0.54
  25. Anirban Maitra · 2 shared papers, 2023–2026 · strength 0.47

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.